AKTS Aktis Oncology, Inc.: institutional ownership and insider trading
117 funds reported holding $1.13B of Aktis Oncology, Inc. in their latest 13F filings; in Q2 2026 funds net sold $13.0M, with 50 new positions and 6 funds selling out; over the last 12 months insiders bought $114M and sold $3.23M on the open market.
Famous investors holding AKTS
- George Soros (Soros Fund Management): $3.22M, 0.0% of the portfolio
- Renaissance Technologies (Renaissance Technologies): $3.07M, 0.0% of the portfolio
- Two Sigma (Two Sigma Investments): $996K, 0.0% of the portfolio
- Ken Griffin (Citadel Advisors): $823K, 0.0% of the portfolio
Largest institutional holders of AKTS
- MPM BioImpact LLC — $156M
- EcoR1 Capital, LLC — $155M
- Blue Owl Capital Holdings LP — $99.0M
- BlackRock, Inc. (BLK) — $73.4M
- T. Rowe Price Investment Management, Inc. — $66.1M
- WELLINGTON MANAGEMENT GROUP LLP — $63.4M
- RTW INVESTMENTS, LP — $51.3M
- RA CAPITAL MANAGEMENT, L.P. — $42.4M
- Jupiter Topco LLC — $42.4M
- BAKER BROS. ADVISORS LP — $32.1M
Recent AKTS insider trades
- Sep 23, 2026: Czibere Akos sold 12,500 shares ($259K)
- Jul 20, 2026: Herrmann Ken sold 4,856 shares ($119K)
- Jul 17, 2026: Herrmann Ken sold 3,065 shares ($77.3K)
- Jul 8, 2026: Ron-Bigger Shulamit sold 50,000 shares ($1.39M)
5%+ owners
- Blue Owl Capital Holdings LP: 5.9% (Schedule 13G, filed May 14, 2026)